Diana Peiteado

Diana Peiteado

Auto-generated profile, based on publicly available information

Diana Peiteado

Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
IMIñigo González Mazón
Iñigo González Mazón
JRJavier Rueda-Gotor
Javier Rueda-Gotor
IFIván Ferraz-Amaro
Iván Ferraz-Amaro
FGFernanda Genre
Fernanda Genre
ACAlfonso Corrales
Alfonso Corrales
Miguel Angel Gonzalez-GayMiguel Angel Gonzalez-Gay
Miguel Angel Gonzalez-Gay

11 November 2022 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
IHIrene Monjo Henry
Irene Monjo Henry
EFE. Fernández Fernández
E. Fernández Fernández
DPD. Peiteado
D. Peiteado
ABAlejandro Balsa
Alejandro Balsa
EME. de Miguel
E. de Miguel

3 March 2017
Verified
Journal Article
Closed access
DPDiana Peiteado
Diana Peiteado
AVAlejandro Villalba
Alejandro Villalba
EMEmilio Martín-Mola
Emilio Martín-Mola
ABAlejandro Balsa
Alejandro Balsa
EMEugenio De Miguel
Eugenio De Miguel


24 May 2024 in RMD Open
Verified
Journal Article
Open access
PDF file
DBDiego Benavent
Diego Benavent
MBMaría Benavent
María Benavent
VFVíctor Fanjul
Víctor Fanjul
JMJavier Arias Manjón
Javier Arias Manjón
VNVictoria Navarro-Compán
Victoria Navarro-Compán
EMEugenio de Miguel
Eugenio de Miguel
Objective This study aims to use a novel technology based on natural language processing (NLP) to extract clinical information from electronic health records (EHRs) to characterise the clinical profile of patients diagnosed with spondyloarthritis (SpA) at a large-scale hospital. Methods An observational, retrospective analysis was conducted on EHR data from all patients with SpA (including psoriatic arthritis (PsA)) at Hospital Universitario La Paz, between 2020 and 2022. Data were collected using Savana Manager, an NLP-based system, enabling the extraction of information from unstructured, free-text EHRs. Variables analysed included demographic data, SpA subtypes, comorbidities and treatments. The performance of the technology in detecting SpA clinical entities was evaluated through precision, recall and F-1 score metrics. Results From a hospital population of 639 474 patients, 4337 (0.7%) patients had a diagnosis of SpA or their subtypes in their EHR. The population predominantly comprised men (55.3%) with a mean age of 50.9 years. Peripheral SpA (including PsA) was reported in 31.6%, axial SpA in 20.9%, both axial and peripheral SpA in 3.7%, while 43.7% of patients did not have the SpA subtype reported. Common comorbidities included hypertension (25.0%), dyslipidaemia (22.2%) and diabetes mellitus (15.5%). The use of conventional disease-modifying antirheumatic drugs (csDMARDs) and biological DMARDs (bDMARDs) was documented, with methotrexate (25.3% of patients) being the most used csDMARDs and adalimumab (10.6% of patients) the most used bDMARD. The NLP technology demonstrated high precision and recall, with all the assessed F-1 score values over 0.80, indicating reliable data extraction. Conclusion The application of NLP technology facilitated the characterisation of the SpA patient profile, including demographics, clinical features, comorbidities and treatments. This study supports the utility of NLP in enhancing the understanding of SpA and suggests its potential for improving patient management by extracting meaningful information from unstructured EHR data.

15 January 2020 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
MRM A Ruiz-Ramirez
M A Ruiz-Ramirez
PRP Rodríguez-Merlos
P Rodríguez-Merlos
CSC Suarez
C Suarez
CPC Plasencia-Rodríguez
C Plasencia-Rodríguez
VNV Navarro-Compán
V Navarro-Compán
MMMARIA DOLORES MARTIN-ARRANZ
MARIA DOLORES MARTIN-ARRANZ
Background: Vedolizumab is a monoclonal antibody that binds to an integrin resulting in gut-selective anti-inflammatory activity. It is indicated for the treatment of inflammatory bowel disease (IBD), both in Crohn’s disease (CD) and ulcerative colitis (UC), but no benefit has been proved on inflammatory joint disease. The aim of this study was to analyse the incidence of the debut of inflammatory joint disease and also analyse the prevalence of outbreak of the previously known joint disease in IBD patients during treatment with vedolizumab. Methods: Descriptive observational study of a prospective cohort of IBD patients treated with vedolizumab. All patients met the following inclusion criteria: adults > 18 years, histological diagnosis of CD or UC and having received or being currently being treated with vedolizumab. Demographic, clinical and analytical information were obtained from the Hospital’s database from both Gastroenterology and Rheumatology clinical records. Results: A total of 44 patients (25 with CD and 19 with UC) were included. Of these, most had been pretreated with anti-TNF (41 switchers and 3 patients näive to biological therapy). The mean age of the included patients was 50 ± 15.4 years with predominantly female (54%). The mean follow-up time of patients in this study was 26 ± 10 months. In total, 13 patients (30%) presented joint symptoms during treatment with vedolizumab (8 with EC and 9 with UC). Of these 13 patients, 3 already had previous diagnosis of inflammatory joint pathology (spondyloarthritis), 6 patients debuted with inflammatory joint symptoms during treatment with vedolizumab and 4 mechanical arthralgias. Of the 6 patients with debut of inflammatory profile symptoms, inflammatory pathology was confirmed in 5 patients (spondyloarthritis) and 1 patient presented osteomuscular mechanical pathology. A total of 11 patients with the diagnosed rheumatological disease (25%) were observed in this cohort. Conclusion: The incidence of inflammatory joint pathology in IBD patients treated with vedolizumab is similar to the one described in other cohorts regardless of the treatment received. Suspension of anti-TNF treatment to switch to vedolizumab may be associated with outbreaks of rheumatic disease. This presents a new challenge in the therapeutic approach, being crucial a multidisciplinary approach.